Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Imifoplatin |
Synonyms | |
Therapy Description |
Imifoplatin (PT-112) is a phosphoplatin that may result in decreased tumor cell growth (PMID: 19020081, PMID: 32117585). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Imifoplatin | PT-112|PT 112 | Chemotherapy - Platinum 7 | Imifoplatin (PT-112) is a phosphoplatin that may result in decreased tumor cell growth (PMID: 19020081, PMID: 32117585). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02266745 | Phase I | Imifoplatin | A Phase 1 Study of PT-112 Injection in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | FRA | 0 |
NCT03288480 | Phase I | Imifoplatin | A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma | Completed | USA | 0 |